Modulation of notch signaling as a therapeutic approach for liver cancer

Current Gene Therapy

Volumn 15, Issue 2, 2015, Pages 171-181

  Wu, Guang ^a   Wilson, George ^a   George, Jacob ^a   Qiao, Liang ^a  

^a University of Sydney   (Australia)

Author keywords

Cancer therapy; HCC; Liver cancer; Notch signaling; Tumor initiation; Tumor progression

Indexed keywords

APOPTOSIS INDUCING FACTOR; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; GAMMA SECRETASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MICRORNA; MICRORNA 199; MICRORNA 200; MICRORNA 34A; NOTCH RECEPTOR; PRESENILIN 2; PROTEIN MDM2; RETINOBLASTOMA PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANGIOGENIC GENE THERAPY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; GENE THERAPY; GENETICS; LIVER CELL; LIVER NEOPLASMS; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MICRORNAS; MOLECULAR TARGETED THERAPY; RECEPTORS, NOTCH;

EID: 84945346384     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523214666141224100319     Document Type: Article

References (113)

1. Hori K, Sen A, Artavanis-Tsakonas S. Notch signaling at a glance. J Cell Sci 2013; 126(Pt 10): 2135-40.
2. Guruharsha KG, Kankel MW, Artavanis-Tsakonas S. The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet 2012; 13(9):654-66.
3. Fryer CJ, Lamar E, Turbachova I, Kintner C, Jones KA. Mastermind mediates chromatin-specific transcription and turnover of the Notch enhancer complex. Genes Dev 2002; 16(11): 1397-411.
4. Miele L. Transcription factor RBPJ/CSL: A genome-wide look at transcriptional regulation. Proc Natl Acad Sci USA 2011; 108(36): 14715-6.
5. Castel D, Mourikis P, Bartels SJ, Brinkman AB, Tajbakhsh S, Stunnenberg HG. Dynamic binding of RBPJ is determined by Notch signaling status. Genes Dev 2013; 27(9): 1059-71.
6. Collins KJ, Yuan Z, Kovall RA. Structure and function of the CSLKyoT2 corepressor complex: a negative regulator of notch signaling. Structure 2014; 22(1): 70-81.
7. Andersen P, Uosaki H, Shenje LT, Kwon C. Non-canonical Notch signaling: emerging role and mechanism. Trends Cell Biol 2012; 22(5): 257-65.
8. Kwon C, Cheng P, King IN, et al. Notch post-translationally regulates beta-catenin protein in stem and progenitor cells. Nat Cell Biol 2011; 13(10): 1244-51.
9. Fischer A, Gessler M. Delta-Notch--and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res 2007; 35(14): 4583-96.
10. Capaccione KM, Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis 2013; 34(7): 1420-30.
11. Hales EC, Taub JW, Matherly LH. New insights into Notch1 regulation of the PI3K–AKT–mTOR1 signaling axis: Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal 2014; 26(1): 149-61.
12. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306(5694): 269-71.
13. Koch U, Radtke F. Notch and cancer: a double-edged sword. Cell Mol Life Sci 2007; 64(21): 2746-62.
14. South AP, Cho RJ, Aster JC. The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol 2012; 23(4): 458-64.
15. Valdez JM, Xin L. The dual nature of Notch in tissue homeostasis and carcinogenesis. Cell Cycle 2013; 12(4): 541.
16. Meyer T. Primary liver cancer. Brit J Cancer 2013; 108(4): 995-6.
17. Dill MT, Tornillo L, Fritzius T, et al. Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology 2013; 57(4): 1607-19.
18. Villanueva A, Alsinet C, Yanger K, et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 2012; 143(6): 1660-9.
19. Huch M, Clevers H. Sox9 marks adult organ progenitors. Nat Genet 2011; 43(1): 9-10.
20. Qi R, An H, Yu Y, et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 2003; 63(23): 8323-9.
21. Lim SO, Kim HS, Quan X, et al. Notch1 binds and induces degradation of Snail in hepatocellular carcinoma. BMC Biol 2011; 9: 83.
22. Viatour P, Ehmer U, Saddic LA, et al. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med 2011; 208(10): 1963-76.
23. Cantarini MC, de la Monte SM, Pang M, et al. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006; 44(2): 446-57.
24. Tschaharganeh DF, Chen X, Latzko P, et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 2013; 144(7): 1530-42.
25. Giovannini C, Gramantieri L, Chieco P, et al. Selective ablation of Notch3 in HCC enhances doxorubicin’s death promoting effect by a p53 dependent mechanism. J Hepatol 2009; 50(5): 969-79.
26. Liu M, Lee DF, Chen CT, et al. IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression. Mol Cell 2012; 45(2): 171-84.
27. Vincent F, Bonnin P, Clemessy M, et al. Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. Cancer Res 2009; 69(7): 2853-60.
28. Xiong YQ, Sun HC, Zhang W, et al. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 2009; 15(15): 4838-46.
29. Tanaka S, Shiraha H, Nakanishi Y, et al. Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma. Int J Cancer 2012; 131(11): 2537-46.
30. Wang XQ, Zhang W, Lui EL, et al. Notch1-Snail1-E-cadherin pathway in metastatic hepatocellular carcinoma. Int J Cancer 2012; 131(3): E163-72.
31. Oskarsson T, Batlle E, Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 2014; 14(3): 306-21.
32. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-74.
33. Dufraine J, Funahashi Y, Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008; 27(38): 5132-7.
34. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell 2009; 139(5): 871-90.
35. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A 2008; 105(17): 6392-7.
36. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000. 100(1): 57-70.
37. Ogunwobi OO, Wang T, Zhang L, Liu C. Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced epithelialmesenchymal transition in human hepatocellular carcinoma. J Gastroenterol Hepatol 2012; 27(3): 566-78.
38. Yang MH, Chen CL, Chau GY, et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 2009; 50(5): 1464-74.
39. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2(6): 442-54.
40. Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest 2013; 123(5): 1911-8.
41. Benjamin B, Cedric B. Unravelling cancer stem cell potential. Nat Rev Cancer 2013; 13(10): 727-38.
42. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003; 3(12): 895-902.
43. Harrison H, Farnie G, Howell SJ, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010; 70(2): 709-18.
44. Hassan KA, Wang L, Korkaya H, et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res 2013; 19(8): 1972-80.
45. Lu J, Fan F, Xia L, et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 2013; 23(2): 171-85.
46. Vidal SJ, Rodriguez-Bravo V, Galsky M, Cordon-Cardo C, Domingo-Domenech J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 2013; 33(36):4451-63.
47. Yanger K, Zong Y, Maggs LR, et al. Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev 2013; 27(7): 719-24.
48. Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest 2012; 122(11): 3914-8.
49. Fan B, Malato Y, Calvisi DF, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest 2012; 122(8): 2911-5.
50. Ma S, Tang KH, Chan YP, et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010; 7(6): 694-707.
51. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011; 9(1): 50-63.
52. Oikawa T, Kamiya A, Zeniya M, et al. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology 2013; 57(4): 1469-83.
53. Oikawa T, Kamiya A Kakinuma S, et al. Sall4 regulates cell fate decision in fetal hepatic stem/progenitor cells. Gastroenterology 2009; 136(3): 1000-11.
54. Wang XQ, Ongkeko WM, Chen L, et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology 2010; 52(2): 528-39.
55. Wan S, Zhao E, Kryczek I, et al. Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells. Gastroenterology 2014; 147(6):1393-404.
56. Nishina S, Shiraha H, Nakanishi Y, et al. Restored expression of the tumor suppressor gene RUNX3 reduces cancer stem cells in hepatocellular carcinoma by suppressing Jagged1-Notch signaling. Oncol Rep 2011; 26(3): 523-31.
57. Zender S, Nickeleit I, Wuestefeld T, et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell 2013; 23(6): 784-95.
58. Guest R, Boulter L, Kendall T, et al. The functional role of Notch3 in intrahepatic cholangiocarcinoma. The Lancet 2014; 383: S13.
59. Ishimura N, Bronk SF, Gores GJ. Inducible Nitric Oxide Synthase Up-Regulates Notch-1 in Mouse Cholangiocytes: Implications for Carcinogenesis. Gastroenterology 2005; 128(5): 1354-68.
60. Mazur PK, Riener MO, Jochum W, et al. Expression and clinicopathological significance of notch signaling and cell-fate genes in biliary tract cancer. Am J Gastroenterol 2012; 107(1): 126-35.
61. Akhoondi S, Sun D, von der Lehr N, et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007; 67(19): 9006-12.
62. Enkhbold C, Utsunomiya T, Morine Y, et al. Loss of FBXW7 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma. Hepatol Res 2014; 44(14):E346-52.
63. El Khatib M, Bozko P, Palagani V, Malek NP, Wilkens L, Plentz RR. Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo. PLoS One 2013; 8(10): e77433.
64. Guo S, Liu M, Gonzalez-Perez RR. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta 2011; 1815(2): 197-213.
65. Gustafsson MV, Zheng X, Pereira T, et al., Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005; 9(5): 617-28.
66. Osipo C, Golde TE, Osborne BA, Miele LA. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest 2008; 88(1): 11-7.
67. Rizzo P, Miao H, D’Souza G, et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008; 68(13): 5226-35.
68. Roti G, Carlton A, Ross KN, et al. Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. Cancer Cell 2013; 23(3): 390-405.
69. Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling-are we there yet? Nat Rev Drug Discov 2014; 13(5): 357-78.
70. Yan M, Callahan CA, Beyer JC, et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 2010; 463(7282): E6-7.
71. Scehnet JS, Jiang W, Kumar SR, et al. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 2007; 109(11): 4753-4760.
72. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006; 444(7122): 1032-7.
73. Tschaharganeh DF, Chen X, Latzko P, et al. Yes-Associated Protein Up-regulates Jagged-1 and Activates the NOTCH Pathway in Human Hepatocellular Carcinoma. Gastroenterology 2013; 144(7): 1530-42.e12.
74. Huntzicker EG, Hotzel K, Choy L, et al. Differential effects of targeting Notch receptors in a mouse model of liver cancer. Hepatology 2014; doi: 10.1002/hep.27566.
75. Wu Y, Cain-Hom C, Choy L, et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010; 464(7291): 1052-7.
76. Villanueva A, Alsinet C, Yanger K, et al. Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice. Gastroenterology 2012; 143(6): 1660-1669.e7.
77. Sun Q, Wang R, Wang Y, Luo J, Wang P, Cheng B. Notch1 is a potential therapeutic target for the treatment of human hepatitis B virus X protein-associated hepatocellular carcinoma. Oncol Rep 2014; 31(2): 933-9.
78. Kunnimalaiyaan S, Gamblin TC, Kunnimalaiyaan M. Role of notch3 in epithelial-to-mesenchymal transition of HCC. Cancer Res 2014; 74(19 Supplement): 5289
79. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137(2): 216-33.
80. Bush G, diSibio G, Miyamoto A, Denault JB, Leduc R, Weinmaster G. Ligand-induced signaling in the absence of furin processing of Notch1. Dev Biol 2001; 229(2): 494-502.
81. Zolkiewska A. ADAM proteases: ligand processing and modulation of the Notch pathway. Cell Mol Life Sci 2008; 65(13): 2056-68.
82. Shih Ie M, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007; 67(5): 1879-82.
83. Wang, F., et al., Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. Oncol Rep, 2012. 27(4): p. 1170-6.
84. Kopan R, Ilagan MXG. Gamma-secretase: proteasome of the membrane? Nat Rev Mol Cell Biol 2004; 5(6): 499-504.
85. Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacol Ther 2013; 139(2): 95-110.
86. Osipo C, Patel P, Rizzo P, et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 2008; 27(37): 5019-32.
87. McAuliffe SM, Morgan SL, Wyant GA, et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A 2012; 109(43): E2939-48.
88. Kitamura T, Kitamura YI, Funahashi Y, et al. A Foxo/Notch pathway controls myogenic differentiation and fiber type specification. J Clin Invest 2007; 117(9): 2477-85.
89. Niimi H, Niimi H1, Pardali K, Vanlandewijck M, Heldin CH, Moustakas A. Notch signaling is necessary for epithelial growth arrest by TGF-beta. J Cell Biol 2007; 176(5): 695-707.
90. Restivo G, Nguyen BC, Dziunycz P, et al. IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes. EMBO J 2011; 30(22): 4571-85.
91. Furukawa S, Furukawa S, Kawasaki Y, Miyamoto M, Hiyoshi M, Kitayama J, Akiyama T. The miR-1-NOTCH3-Asef pathway is important for colorectal tumor cell migration. PLoS One 2013; 8(11): e80609.
92. Wang Z, Da Silva TG, Jin K, et al. Notch Signaling Drives Stemness and Tumorigenicity of Esophageal Adenocarcinoma. Cancer Res 2014; 74(21):6364-74.
93. Krejci A, Bray S. Notch activation stimulates transient and selective binding of Su(H)/CSL to target enhancers. Genes Dev 2007; 21(11): 1322-7.
94. Weaver KL, Alves-Guerra MC, Jin K, et al. NACK is an integral component of the Notch transcriptional activation complex and is critical for development and tumorigenesis. Cancer Res 2014; 74(17):4741-51.
95. Matsuoka S, Oike Y, Onoyama I, et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev 2008; 22(8): 986-91.
96. Saj A, Arziman Z, Stempfle D, et al. A combined ex vivo and in vivo RNAi screen for notch regulators in Drosophila reveals an extensive notch interaction network. Dev Cell 2010; 18(5): 862-76.
97. Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM, Zhang GZ. Biological functions of microRNAs: a review. J Physiol Biochem 2011; 67(1): 129-39.
98. Wang Z, Li Y, Kong D, Ahmad A, Banerjee S, Sarkar FH. Crosstalk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett 2010; 292(2): 141-8.
99. Datta J, Kutay H, Nasser MW, et al. Methylation Mediated Silencing of MicroRNA-1 Gene and Its Role in Hepatocellular Carcinogenesis. Cancer Res 2008; 68(13): 5049-58.
100. Kwon C, Han Z, Olson EN, Srivastava D. MicroRNA1 influences cardiac differentiation in Drosophila and regulates Notch signaling. Proc Natl Acad Sci USA 2005; 102(52): 18986-91.
101. Ivey KN, Muth A, Arnold J, et al. MicroRNA Regulation of Cell Lineages in Mouse and Human Embryonic Stem Cells. Cell Stem Cell 2008; 2(3): 219-29.
102. Li Y, Guessous F, Zhang Y, et al. MicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes. Cancer Res 2009; 69(19): 7569-76.
103. Xu Y, Liu L, Liu J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 2011; 128(2): 412-7.
104. Wang Z, Wu J, Zhang G, Cao Y, Jiang C, Ding Y. Associations of miR-499 and miR-34b/c Polymorphisms with Susceptibility to Hepatocellular Carcinoma: An Evidence-Based Evaluation. Gastroenterol Res Pract 2013; 2013: 1-8.
105. Xie K, Liu J, Chen J, et al. Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer. Gene 2014; 543(1): 101-7.
106. Garzia L, Andolfo I, Cusanelli E, et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One 2009; 4(3): e4998.
107. Hou J, Lin L, Zhou W, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19(2): 232-43.
108. Vallejo DM, Caparros E, Dominguez M. Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. EMBO J 2011; 30(4): 756-69.
109. Brabletz S, Bajdak K, Meidhof S, et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J 2011; 30(4): 770-82.
110. Hung CS, Liu HH, Liu JJ, et al. MicroRNA-200a and-200b mediated hepatocellular carcinoma cell migration through the epithelial to mesenchymal transition markers. Ann Surg Oncol 2013; 20 Suppl 3: S360-8.
111. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11(12): 849-64.
112. Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol 2013; 31(7): 577.
113. Ding Y, Wang W, Feng M, et al. A biomimetic nanovectormediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 2012; 33(34): 8893-905.